NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
07/13/2024
Back to search
Official data from USPTO
BRAFTOVI ENCORAFENIB CAPSULES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
07/13/2024
Trademark type
Combined
Nice classes
5
Filing date
01/16/2018
Registration date
12/11/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/13/2024
Last transaction
07/13/2024
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/02/2018
First use in commerce
07/02/2018
Drawing code
3
Owner type
03
Owner location
Boulder, CO
Examiner
TAYLOR, DAVID
Current location
Historical data usage
Mark description
The mark consists of three sphere designs diagonally above the word "BRAFTOVI" over the words encorafenib capsules, wherein the term encorafenib is in parentheses.
Holders and representatives
Holders
Array Biopharma Inc.
Representatives
Heather A. McDonald Pfizer Inc.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; Anti-inflammatories; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Antivirals; Cardiovascular pharmaceuticals; Dermatological pharmaceutical products; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the prevention and treatment of cancer and tumors; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
35 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
07/13/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/13/2024
E815
TEAS SECTION 8 & 15 RECEIVED
01/02/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/11/2023
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
11/16/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/16/2020
ES7R
TEAS SECTION 7 REQUEST RECEIVED
07/16/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/04/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/04/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/04/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/04/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/04/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
12/11/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/25/2018
PUBO
PUBLISHED FOR OPPOSITION
09/25/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/05/2018
ALIE
ASSIGNED TO LIE
08/21/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/09/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
08/09/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/09/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
08/09/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/09/2018
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
07/13/2018
IUAA
USE AMENDMENT ACCEPTED
07/12/2018
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
07/11/2018
IUAF
USE AMENDMENT FILED
07/11/2018
EAAU
TEAS AMENDMENT OF USE RECEIVED
07/10/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/03/2018
GNRT
NON-FINAL ACTION E-MAILED
05/03/2018
CNRT
NON-FINAL ACTION WRITTEN
05/03/2018
DOCK
ASSIGNED TO EXAMINER
04/26/2018
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
01/30/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/28/2018
NWAP
NEW APPLICATION ENTERED
01/19/2018
Continuous trademark protection
Get notified about every new filing that threatens BRAFTOVI ENCORAFENIB CAPSULES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.